An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...
French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback